Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Oncology Best Practice™: The Latest Advances on PI3K Inhibition in Breast Cancer: What You Need to Know
Oncology Best Practice™:
The Latest Advances on PI3K Inhibition in Breast Cancer: What You Need to Know
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
This educational activity will bring leading clinical experts in the management of patients with breast cancer using phosphoinositide 3-kinase (PI3K) inhibitors. Best practices for identification of patients with breast cancer who are most likely to benefit from these agents, the specific mechanistic characteristics of available agents, and techniques for managing adverse events appropriately will all be covered in this in-depth program. In addition, available clinical trial data will be covered and contextualized in patient cases, including trials of emerging strategies utilizing combination approaches incorporating PI3K inhibition. This program will include an in-depth discussion to optimize use of PI3K inhibitors using the most advanced and most accurate available tumor testing technologies.
Benefits of Attending
- Update and confirm your practice with the best practices in the management of patients for with advanced breast cancer
- Learn the best approaches for identification of trials of PI3K inhibitors that may be appropriate for selected patients with breast cancer
- Through in-depth review of clinical trials in progress, learn the latest developments on PI3K inhibitors in breast cancer
- Recognize the toxicity profile of PI3K inhibitors and how this may affect treatment decisions as an expanding array of targeted therapies and combinations become available in breast cancer
This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.
- Discuss that rationale supporting the role of PI3K inhibition in the treatment of patients with breast cancer
- Review data from recent clinical trials evaluating efficacy and safety of PI3K inhibitors in breast cancer treatment
- Examine strategies for optimizing treatment outcomes and patient selection for PI3K inhibition
- Discuss effective strategies to proactively counsel and manage adverse events associated with PI3K inhibition in the treatment of patients with breast cancer
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, NY